DESIGN THERAPEUTICS INC (DSGN) Stock News

NASDAQ:DSGN - US25056L1035 - Common Stock

6.45 USD

+0.34 (+5.56%)

Last: 9/5/2025, 8:08:58 PM

6.45 USD

0 (0%)

After Hours: 9/5/2025, 8:08:58 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DSGN Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Benzinga - Mentions: IVVD

Steven Cohen's Biotech Bets Are Getting Bolder — And Smaller

11 days ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

11 days ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

a month ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

a month ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

3 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

3 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

3 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

4 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

4 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

4 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

4 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

4 months ago - By: Yahoo Finance - Mentions: LRCX IBM MA ABBV ...

Lam Research Corporation (LRCX): Jim Cramer Is Blunt — “Lam Is a Gem”

4 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

5 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

5 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

5 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

5 months ago - By: Bright Peak Therapeutics, Inc. - Mentions: ANAB XERS

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

5 months ago - By: Benzinga - Mentions: IRIX LXRX PTIX DBVT ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

6 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

6 months ago - By: Design Therapeutics, Inc.

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

6 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

6 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

10 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

10 months ago - By: Design Therapeutics, Inc.

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences